Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3471851 in Participants With Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have a confirmed diagnosis of atopic dermatitis (AD) for least 12 months~* Have active AD according to study specific criteria~* Be willing and able to undergo skin biopsies~Exclusion Criteria:~* Have received certain topical medications for AD within 14 days prior to baseline~* Have received certain systemic medications for AD within 4 weeks prior to baseline~* Have received LY3471851 previously

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 10 µg/kg LY3471851 (Type: ACTIVE_COMPARATOR): Participants received subcutaneous (SC) injection of 10 microgram per kilogram (μg/kg) LY3471851 every 2 weeks for a treatment period of 12 weeks.
- 12 µg/kg LY3471851 (Type: ACTIVE_COMPARATOR): Participants received subcutaneous injection of 12 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
- 24 µg/kg LY3471851 (Type: ACTIVE_COMPARATOR): Participants received subcutaneous injection of 24 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received subcutaneous injection of placebo every 2 weeks for a treatment period of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).